Abstract: Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.

Abstract: Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.

Abstract: Peripheral intravenous (IV) waveform analysis (PIVA) systems and methods for determining an intravascular volume status of a living subject and monitoring an IV line functionality of a peripheral IV device are provided. The PIVA system includes a peripheral IV device and a processing device. The peripheral IV device includes a peripheral IV catheter inserted into a vein of the living subject, and a fluid controlling device to control fluid flow from a fluid source to the peripheral IV catheter. The processing device receives peripheral venous signals from the peripheral IV device, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum; and performs a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine an intravascular volume status of the living subject and/or an IV line functionality of the peripheral IV catheter in real time.

Abstract: Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.

Abstract: Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.

Abstract: Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.

Abstract: The present disclosure relates to compounds comprising (i) an active agent, wherein the active agent includes a charge at a predetermined pH, (ii) a polymer, wherein the polymer includes an opposite charge than the active agent at the predetermined pH; and (iii) a polyplex comprising the peptide and the polymer electrostatically bond together at the predetermined pH. In some embodiments, the active agent is a peptide, such as a peptide comprising MAPKAP kinase II inhibitory peptide, and in some embodiments the peptide includes a cell-penetrating peptide. In further embodiments, the disclosure provides methods for treating a disease or condition by administering a composition according to the present disclosure to a subject in need thereof.

Abstract: One aspect of the present disclosure is a system for hemodynamic resuscitation. The system includes an intravenous access device having a pressure sensor element configured to detect a peripheral venous pressure value in response to an occlusion of a peripheral vein. The system also includes a controller device that is configured to receive a signal from the pressure sensor comprising the peripheral venous pressure value, to process the signal to determine a hemodynamic parameter based on the peripheral venous pressure value, and to generate a resuscitation score based on the hemodynamic parameter.

Abstract: The described invention provides a method for treating myocardial infarction (MI) in a subject comprising administering to the subject a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof made from a fusion between a first polypeptide that is a cell permeable protein (CPP) selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 2), WLRRIKAWLRRIKA (SEQ ID NO: 21), WLRRIKA (SEQ ID NO: 22), YGRKKRRQRRR (SEQ ID NO: 23), FAKLAARLYR (SEQ ID NO: 25), and KAFAKLAARLYR (SEQ ID NO: 26), and a second polypeptide that is a therapeutic domain (TD), and a pharmaceutically acceptable carrier. The described invention also provides a kit comprising a composition comprising at least one MK2 inhibitor peptide; a means for administering the composition; and a packaging material.

Abstract: Aspects of the invention relates to systems and methods for monitoring an intravenous (IV) line functionality of an IV device. The system includes an IV catheter to be inserted into the vein of the living subject, at least one pressure sensor in fluid communication with the IV catheter to acquire peripheral venous signals; and a processing device. The processing device receives the peripheral venous signals from the pressure sensor, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum, and determines an IV line functionality of the IV catheter in real time, wherein the IV line functionality of the IV catheter indicates IV infiltration when amplitude decreases greater than a first threshold are detected from the peaks of the peripheral venous pressure frequency spectrum.

Abstract: The described invention provides compositions and methods for treating asthma, a disease, condition or pathologic process whose progression is characterized by one or more of aberrant fibroblast proliferation and extracellular matrix deposition producing constriction in an airway, airway remodeling, and airway obstruction in lung tissue. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce the constriction of small airway dimensions and airway obstruction, treat airway remodeling, or a combination thereof.

Abstract: Aspects of the invention relates to systems and methods for monitoring an intravenous (IV) line functionality of an IV device. In one embodiment, the system includes an IV catheter to be inserted into the vein of the living subject, at least one pressure sensor in fluid communication with the IV catheter to acquire peripheral venous signals; and a processing device. The processing device receives the peripheral venous signals from the pressure sensor, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum, and then performs a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine an IV line functionality of the IV catheter in real time. When the IV line functionality indicates IV infiltration, the processing device may control the fluid controlling device to stop the fluid flow from the fluid source to the IV catheter.

Abstract: The described invention provides compositions and methods for reducing progression of a fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the progression of the fibrosis being characterized by aberrant fibroblast proliferation and extracellular matrix deposition in the tissue. The method includes administering a therapeutic amount of a pharmaceutical composition containing a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce progression of the fibrosis, to treat remodeling of the tissue, or a combination thereof.

Abstract: Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.

Abstract: Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.

Abstract: A method of measuring peripheral venous pressure includes providing a tubing operably connected between a fluid source and a vein, a fluid controlling device for occluding the tubing and configured to have an on position and an off position, and at least one pressure sensor in fluid communication with the tubing, placed between the fluid controlling device and the vein; selectively passing fluid from the fluid source to the vein, through the tubing, by the fluid controlling device; measuring both a fluid pressure from the fluid source and a distal venous pressure from the vein by the at least one pressure sensor when the fluid controlling device is in the on position; and measuring the distal venous pressure from the vein only by the at least one pressure sensor when the fluid controlling device is in the off position.

Abstract: The described invention provides a method for treating myocardial infarction (MI) in a subject comprising administering to the subject a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof made from a fusion between a first polypeptide that is a cell permeable protein (CPP) selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 2), WLRRIKAWLRRIKA (SEQ ID NO: 21), WLRRIKA (SEQ ID NO: 22), YGRKKRRQRRR (SEQ ID NO: 23), FAKLAARLYR (SEQ ID NO: 25), and KAFAKLAARLYR (SEQ ID NO: 26), and a second polypeptide that is a therapeutic domain (TD), and a pharmaceutically acceptable carrier. The described invention also provides a kit comprising a composition comprising at least one MK2 inhibitor peptide; a means for administering the composition; and a packaging material.

Abstract: Devices, systems, and methods for filtering medical device noise artifacts from circulatory waveform signals are disclosed. A circulatory pressure is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain measurements are filtered to generate a filtered time-domain signal, by removing active pumping periods. The filtered time-domain signal is transformed into a frequency-domain signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. Peaks may be adjusted based on a ratio that considers removed signals. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.

Abstract: In one aspect, an apparatus for measuring peripheral venous pressure includes a tubing having two ends with one end connectable to a fluid source and the other end connectable to a vein, a fluid controlling device configured to have an on position and an off position, and at least one pressure sensor configured to measure fluid pressures therein. When the fluid controlling device is in the on position, fluid flow in the tubing is allowed to pass through the fluid controlling device, such that the at least one pressure sensor measures both a fluid pressure from the fluid source and a distal venous pressure from the vein. When the fluid controlling device is in the off position, no fluid flow in the tubing is allowed to pass through the fluid controlling device, such that the at least one pressure sensor measures the distal venous pressure from the vein only.

Abstract: The described invention provides pharmaceutical formulations comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof with improved stability and bioavailability.